STAKEHOLDERS BRIEFING

Accelerating Innovation for Pediatric ARV Formulations:
Review of Progress of Mutual Accountability Framework

Tuesday 21 July 2015, 12:30 to 2:30pm
Room 215-216, Vancouver Convention Centre

Organized by the Pediatric HIV Treatment Initiative and
the Global Pediatric ARV Commitment-to-Action

BACKGROUND

Please join us for a High-level Stakeholder Briefing at the 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. The briefing will include updates from the Paediatric Treatment Initiative and the Global Pediatric ARV Commitment-to-Action. A high-level panel discussion on overcoming challenges and advancing opportunities to accelerate product innovation and market uptake of new pediatric ARV formulations will follow.

ABOUT THE ORGANIZERS OF THE EVENT

GLOBAL PEDIATRIC ARV COMMITMENT-TO-ACTION (CTA)
On World AIDS Day 2014, the U.S. President Emergency Plan for AIDS Relief (PEPFAR), the Pediatric HIV Treatment Initiative (PHTI), and the Global Fund to Fight AIDS, TB and Malaria announced a new Global Pediatric ARV Commitment-to-Action (CTA). The HIV Medicines Research Industry Forum endorsed the CTA on the same day. The CTA brings together leading organizations to accelerate the development and approval of new, high-priority pediatric ARV co-formulations for first- and second-line treatment by the end of 2016.

PEDIATRIC HIV TREATMENT INITIATIVE (PHTI)
The PHTI is a collaboration among UNITAID, the Medicines Patent Pool, Drugs for Neglected Diseases initiative (DNDi), and the Clinton Health Access Initiative (CHAI) — with the World Health Organization (WHO) as technical partner. Launched in May 2014 at the 67th World Health Assembly, the PHTI seeks to catalyze the development of, and accelerate access to, new, better-adapted pediatric ARVs formulations to improve treatment for children living with HIV.
AGENDA

Light lunch will be served

12:30 – 12:40pm  Welcome  
Mr Robert Matiru, Director, Operations a.i., UNITAID

12:40 – 12:50pm  Introductory Remarks  
Ambassador Deborah Birx, U.S. Global AIDS Coordinator and U.S. Special  
Representative for Global Health Diplomacy, U.S. Department of State

12:50 – 1:10pm  PHTI Progress Report: Product Development Plan, Development Challenges and Next Steps  
Moderated by: Mr. Robert Matiru  
Mr Fernando Pascual, PHTI Interim Coordinator  
Mr Sandeep Juneja, Business Development Director, MPP  
Dr Marc Lallemant, Head Paediatric HIV Program, DNDi  
Dr Martina Penazzato, Paediatric Technical Advisor, HIV Department/WHO

1:10 – 1:30pm  Commitment-to-Action Mutual Accountability Framework  
Moderated by: Mr. Robert Matiru  
Mr. Arjun Vasan, Program Officer, Results for Development Institute

1:30 – 2:30 High-level Panel Discussion: Accelerating Innovation for Pediatric ARV Formulations  
The panel will discuss the progress of current efforts and potential additional strategies to accelerate the development and delivery of priority ARV formulations for children. Participants will address the following challenges: (a) the development of drugs and formulations that have not been developed by originators; (b) attracting interest of generic manufacturers in a small, fragmented market; (c) and the roles of high-level initiatives like the CTA and PHTI, as well as other stakeholders, in spurring innovation for pediatric ARV formulations.  

Moderated by: Dr Robert Hecht, Managing Director, Results for Development Institute  
• Ambassador Deborah Birx, U.S. Global AIDS Coordinator and U.S. Special Representative for Global Health Diplomacy, U.S. Department of State  
• Dr Gottfried Hirnschall, Director, Department of HIV and Global Hepatitis Programme, World Health Organization  
• Mr Martin Auton, Senior Specialist, Lead for the Sourcing of HIV Products, Global Fund  
• Mr Fernando Pascual, PHTI Interim Coordinator  
• Mr Robert Matiru, Director, Operations a.i., UNITAID  
• Dr Marc Lallemant, Head Paediatric HIV Program, DNDi  
• Dr David Ripin, Executive Vice President, Access, and Chief Scientific Officer, CHAI  
• Dr Manuel Gonçalves, Vice President, External Affairs and Communications, ViiV Healthcare  
• Mr Bhavesh Shah, Vice President –International Marketing at Hetero Drugs Ltd